Radspherin
Peritoneal Metastases from Ovarian Cancer
Key Facts
About Oncoinvent
Oncoinvent's mission is to transform cancer care through targeted alpha-particle therapy, specifically for cancers that spread to body cavities. Its core achievement is the development of Radspherin, a first-in-class intraperitoneal alpha-emitting radiopharmaceutical currently in Phase 2 clinical trials. The company's strategy leverages the deep radiopharma expertise of its founders—inventors of the approved drug Xofigo®—and an integrated in-house manufacturing capability to advance its pipeline and establish a new treatment paradigm for regional metastatic disease.
View full company profileAbout Oncoinvent
Oncoinvent's mission is to transform cancer care through targeted alpha-particle therapy, specifically for cancers that spread to body cavities. Its core achievement is the development of Radspherin, a first-in-class intraperitoneal alpha-emitting radiopharmaceutical currently in Phase 2 clinical trials. The company's strategy leverages the deep radiopharma expertise of its founders—inventors of the approved drug Xofigo®—and an integrated in-house manufacturing capability to advance its pipeline and establish a new treatment paradigm for regional metastatic disease.
View full company profileAbout Oncoinvent
Oncoinvent's mission is to transform cancer care through targeted alpha-particle therapy, specifically for cancers that spread to body cavities. Its core achievement is the development of Radspherin, a first-in-class intraperitoneal alpha-emitting radiopharmaceutical currently in Phase 2 clinical trials. The company's strategy leverages the deep radiopharma expertise of its founders—inventors of the approved drug Xofigo®—and an integrated in-house manufacturing capability to advance its pipeline and establish a new treatment paradigm for regional metastatic disease.
View full company profileAbout Oncoinvent
Oncoinvent's mission is to transform cancer care through targeted alpha-particle therapy, specifically for cancers that spread to body cavities. Its core achievement is the development of Radspherin, a first-in-class intraperitoneal alpha-emitting radiopharmaceutical currently in Phase 2 clinical trials. The company's strategy leverages the deep radiopharma expertise of its founders—inventors of the approved drug Xofigo®—and an integrated in-house manufacturing capability to advance its pipeline and establish a new treatment paradigm for regional metastatic disease.
View full company profile